INTRA-CAVITY RONKOLEUKIN IMMUNOTHERAPY IN TREATMENT RESISTANT PATIENTS WITH MALIGNANT EFFUSIONS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study evaluated feasibility, safety and effectiveness in combination with recombinant interleukin-2 (IL2) used for antitumor immunotherapy. The clinical study involved cancer patients with metastatic effusions resistant to systemic chemotherapy. The results showed that intra-cavity IL2-immunotherapy was highly effective and well tolerated in treatment of patients with malignant effusions.

Full Text

Restricted Access

About the authors

K. Tltov

Moscow Clinical Research Centre

Email: ks-titov@mail.ru
Candidate of Medical Sciences

M. Klselevsky

N.N. Blokhin Russian Cancer Research Centre

Professor

I. Shublna

N.N. Blokhin Russian Cancer Research Centre

Doctor of Biological Sciences

R. Izrallov

Moscow Clinical Research Centre

Professor

N. Semenov

Moscow Clinical Research Centre

References

  1. Сельчук В.Ю., Бычков М.Б., Киселевский М.Б. Опухолевые серозиты / М.: Практическая медицина, 2011; с. 278.
  2. Титов К.С., Демидов Л.В, Шубина И.Ж. и др. Сравнение эффективности и переносимости внутрибрюшинной клеточной и ИЛ-2-иммунотерапии у больных с химиорезистентными асцитными формами рака желудка // Рос. онкол. журн. - 2014; 3: 24-8.
  3. Киселевский М.В. Адоптивная иммунотерапия при злокачественных опухолях // Вестник РАМН. - 2003; 1: 40-4.
  4. Xue S., Stauss H. Enhancing immune responses for cancer therapy // Cell Mol. Immunol. - 2007; 4 (3): 173-84.
  5. Manjili M. Revisiting cancer immunoediting by understanding cancer immune complexity // J. Pathol. - 2011; 224 (1): 5-9.
  6. Wang E., Panelli M., Monsurrô V. et al. A global approach to tumor immunology // Cell Mol. Immunol. - 2004; 1 (4): 256-65.
  7. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects // J. Intern. Med. - 2009; 1: 154-81.
  8. June C. Adoptive T cell therapy for cancer in the clinic // J. Clin. Invest. -2007; 117 (6): 1466-76.
  9. Rosenberg S., Lotze M., Yang J. et al. Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer // J. Natl. Cancer Inst. - 1993; 85 (8): 622-32.
  10. Hontscha C., Borck Y., Zhou H. et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) // J. Cancer Res. Clin. Oncol. -2011; 137 (2): 305-10.
  11. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors // J. Cancer. - 2011; 2: 363-8.
  12. Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2 // Chin. Med. Sci. J. - 1993; 8(3): 186-9.
  13. Ruggeri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants // Science. - 2002; 295: 2097-100.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House